Norwegian seafood byproduct and health supplement firm Hofseth Biocare (HBC) has reported a mixed set of results for 2021, with losses deepening even as operating revenue grew impressively.
The company, which has been loss-making for some time on the back of heavy investment in its production capacity and R&D facilities, saw its losses grow both in the fourth quarter of 2021 and the year as a whole [...]
Want to keep reading?
Sign up for a trial to have full access to our articles for 7 days!
Have an account? Log in here:
Enter the email address associated with your account. We'll send you instructions to reset your password.
We’ve sent a link to to change your password.
Please check your inbox to reset your password securely and easily.
redirecting...
